Literature DB >> 9584264

Improvement in exercise tolerance in isovaleric acidaemia with L-carnitine therapy.

P J Lee1, E L Harrison, M G Jones, R A Chalmers, J V Leonard, B J Whipp.   

Abstract

The effect of 4 weeks' treatment with oral-L-carnitine (100 mg/kg per day) on carnitine status and metabolic parameters during an incremental ramp exercise test in a 12-year-old girl with isovaleric acidaemia was examined to determine its possible therapeutic role. The maximum work rate achieved increased from 110 to 120 watts; oxygen consumption at anaerobic threshold from 600 to 800 L/min; peak oxygen consumption from 1270 to 1450 L/min; and oxygen pulse, a measure of cardiac output, from 7.0 to 8.1 L/beat. These changes were associated with increases in plasma and urinary free and acyl carnitine concentrations but no change in physical activity. This observed effect of L-carnitine on exercise performance may be on cardiac or skeletal muscle function or both. We conclude that, in this single patient with isovaleric acid-aemia, L-carnitine supplementation had objective benefits and further studies on more patients are warranted.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9584264     DOI: 10.1023/a:1005391508917

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  11 in total

1.  Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects.

Authors:  S Ahmad; H T Robertson; T A Golper; M Wolfson; P Kurtin; L A Katz; R Hirschberg; R Nicora; D W Ashbrook; J D Kopple
Journal:  Kidney Int       Date:  1990-11       Impact factor: 10.612

2.  Long-term L-carnitine treatment in isovaleric acidemia.

Authors:  E Mayatepek; T W Kurczynski; C L Hoppel
Journal:  Pediatr Neurol       Date:  1991 Mar-Apr       Impact factor: 3.372

3.  Reproducibility and validity of an epidemiologic questionnaire to assess past year physical activity in adolescents.

Authors:  D J Aaron; A M Kriska; S R Dearwater; J A Cauley; K F Metz; R E LaPorte
Journal:  Am J Epidemiol       Date:  1995-07-15       Impact factor: 4.897

Review 4.  L-Carnitine.

Authors:  J H Walter
Journal:  Arch Dis Child       Date:  1996-06       Impact factor: 3.791

5.  Glycine therapy in isovaleric acidemia.

Authors:  M Yudkoff; R M Cohn; R Puschak; R Rothman; S Segal
Journal:  J Pediatr       Date:  1978-05       Impact factor: 4.406

6.  Urinary excretion of l-carnitine and acylcarnitines by patients with disorders of organic acid metabolism: evidence for secondary insufficiency of l-carnitine.

Authors:  R A Chalmers; C R Roe; T E Stacey; C L Hoppel
Journal:  Pediatr Res       Date:  1984-12       Impact factor: 3.756

7.  The response to L-carnitine and glycine therapy in isovaleric acidaemia.

Authors:  C de Sousa; R A Chalmers; T E Stacey; B M Tracey; C M Weaver; D Bradley
Journal:  Eur J Pediatr       Date:  1986-02       Impact factor: 3.183

8.  Effects of L- and DL-carnitine on patients with impaired exercise tolerance.

Authors:  S Watanabe; R Ajisaka; T Masuoka; T Yamanouchi; T Saitou; M Toyama; N Takeyasu; K Sakamoto; Y Sugishita
Journal:  Jpn Heart J       Date:  1995-05

9.  Carnitine metabolism during exercise in patients on chronic hemodialysis.

Authors:  W R Hiatt; B J Koziol; J I Shapiro; E P Brass
Journal:  Kidney Int       Date:  1992-06       Impact factor: 10.612

10.  Intravenous L-carnitine and acetyl-L-carnitine in medium-chain acyl-coenzyme A dehydrogenase deficiency and isovaleric acidemia.

Authors:  J L Van Hove; S G Kahler; D S Millington; D S Roe; D H Chace; S J Heales; C R Roe
Journal:  Pediatr Res       Date:  1994-01       Impact factor: 3.756

View more
  1 in total

1.  L-carnitine in inborn errors of metabolism: what is the evidence?

Authors:  J H Walter
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.